

Microbiological profile of ozenoxacin

Ian Morrissey¹, Rafael Cantón^{2,3}, Jordi Vila^{3,4,5}, Domingo Gargallo-Viola⁶, Ilonka Zsolt^{*,7}, Maria Garcia-Castillo^{2,3} & Yuly López⁵

¹IHMA Europe Sàrl, Monthey, Switzerland

²Servicio de Microbiología, Hospital Universitario Ramón y Cajal & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

³Red Española de Investigación en Patología Infecciosa (REIPI), Instituto de Salud Carlos III, Madrid, Spain

⁴Microbiology Service, Biomedical Diagnostic Center, Hospital Clinic, University of Barcelona, Spain

⁵Institute of Global Health of Barcelona (ISGlobal), Barcelona, Spain

⁶ABAC Therapeutics, Barcelona, Spain

⁷Medical Department, Ferrer Internacional, Barcelona, Spain

*Author for correspondence: izsolt@ferrer.com

Aim: To explore the antibacterial spectrum of ozenoxacin and compare its *in vitro* activity with that of other antibacterial agents. **Materials & methods:** In 2010, 10,054 isolates were collected from 128 centers worldwide. Minimum inhibitory concentrations against Gram-positive and Gram-negative isolates were determined for 23 and 13 antibacterial agents, respectively. **Results:** Ozenoxacin exhibited high *in vitro* activity against susceptible, and methicillin- or levofloxacin-resistant, Gram-positive bacteria. Ozenoxacin was one or two dilutions less active against Enterobacteriaceae isolates, except for *Escherichia coli*, than other quinolones. **Conclusion:** Ozenoxacin is a potent antimicrobial agent mainly against susceptible and resistant strains of Gram-positive isolates (staphylococci and streptococci), and shows activity against some Gram-negative isolates.

First draft submitted: 26 March 2019; Accepted for publication: 9 May 2019; Published online: 28 May 2019

Keywords: antibacterial activity • clinical isolates • Gram-negative • Gram-positive • ozenoxacin • respiratory tract infections • skin and soft tissue infections

Impetigo is a common bacterial skin infection affecting children and adults that is caused by *Staphylococcus aureus* or *Streptococcus pyogenes*. It is the most common bacterial skin infection in children aged 2–5 years [1,2].

Impetigo is commonly treated with topically applied antibacterial agents such as mupirocin, fusidic acid and retapamulin [1–5]. A recent evidence-based review supported the clinical efficacy of mupirocin and fusidic acid for treatment of impetigo [5]. However, in some cases, development of resistant isolates limits the uses of these agents [1,5].

An alternative option for treating impetigo in children and adults is a 1% topical cream formulation of ozenoxacin, a nonfluorinated quinolone with bactericidal activity [6], which was recently approved in several countries worldwide [7–10]. Approval of ozenoxacin was granted based on demonstrable clinical benefit in two large Phase III trials of impetigo involving adults and children from 2 months of age [11,12]. Rapid eradication of bacterial load is important in impetigo to hasten symptom resolution and limit person-to-person transmission of infection.

Early *in vitro* characterization of ozenoxacin found that it was 3- to 321-fold more active than other quinolones against quinolone-susceptible and quinolone-resistant Gram-positive bacteria [13]. A subsequent and more comprehensive study showed that ozenoxacin has potent antibacterial activity against staphylococci and streptococci, irrespective of their levofloxacin susceptibility status [14].

This article presents additional surveillance study data generated during development of ozenoxacin. The antibacterial activity of ozenoxacin against Gram-positive and Gram-negative clinical isolates was compared with that of other topical and systemic antibiotics used in the treatment of skin and soft tissue infections (SSTIs). As it had yet to be decided at the time of the study whether ozenoxacin was to be developed as a systemic (oral or intravenous) and/or topical formulation, in order to ascertain its full microbiological profile, its antibacterial

activity was also investigated against Gram-positive and Gram-negative bacteria causing respiratory tract infections (RTIs) and urinary tract infections (UTIs).

Methods

Clinical isolates collection

During 2010, a total of 10,054 bacterial isolates were collected from 128 centers, with some sites collecting isolates from more than one hospital. Centers were located in the USA (n = 28); Germany (n = 15); France (n = 8); Turkey (n = 8); the United Kingdom (n = 7); Spain (n = 6); Italy (n = 5); Belgium, Canada, Greece, Portugal and South Africa (n = 4 each); Argentina, Australia, Austria, Czech Republic, Japan, Philippines, Slovak Republic, Thailand (n = 2 each); and Hong Kong, Hungary, Ireland, Israel, Malaysia, New Zealand, Poland, Romania, South Korea, Sweden, Switzerland, Taiwan and The Netherlands (n = 1 each).

Isolates were derived from SSTIs (44.8%), RTIs (38.1%), UTIs (1.3%) unknown (8.4%) or other (7.5%) sources. Taxonomic classification of isolates is summarized in Table 1. Isolates were identified following standard microbiological methods, including biochemical test and mass spectrometry (MALDI TOF MS).

Minimum inhibitory concentration determination

Minimum inhibitory concentration (MIC) was determined using broth microdilution methods as recommended by the Clinical and Laboratory Standards Institute (CLSI) [15–17].

Susceptibility was determined using breakpoints set by the CLSI [15,17], except that British Society for Antimicrobial Chemotherapy (BSAC) breakpoints were used for fusidic acid and mupirocin against staphylococci [18].

S. aureus ATCC 29213, *S. pneumoniae* ATCC 49619, *Escherichia coli* ATCC 25922 and *E. coli* ATCC 35218 isolates were used for quality control. All quality control results were within the ranges specified by the CLSI [17,19].

Concentrations of antibacterial agent tested for each isolate are shown in Table 2.

Results

Classification of clinical isolates

Gram-positive bacteria included in the study as principle pathogens were: coagulase-negative staphylococci (CNS), *S. aureus*, β -haemolytic streptococci, viridans streptococci, *S. pneumoniae* and enterococci (Table 1). A high proportion of Gram-positive isolates (69.5% of CNS [618/889]; 63.3% of *S. aureus* [1518/2398]; 78.8% of β -haemolytic streptococci [953/1210]; 66.2% of viridans streptococci [353/533]; and 50.6% of enterococci [84/166]) were derived from SSTIs.

Gram-negative bacteria included in the study as principle pathogens were: Enterobacteriaceae (n = 3190), *Haemophilus* spp. (n = 548) and *Moraxella catarrhalis* (n = 180) (Table 1). A high proportion of Gram-negative isolates classified as *Haemophilus* spp. (95.8%; 525/548) or *M. catarrhalis* (93.9%; 169/180) were derived from RTIs. Similarly, a high proportion of Gram-positive *S. pneumoniae* isolates (90.9%; 843/927) were derived from RTIs.

Comparative antimicrobial activity

Gram-positive bacteria

Staphylococci

Ozenoxacin was highly active against staphylococci with a MIC₉₀ of 0.25 mg/l against *S. aureus* and all CNS isolates (Table 3). In general, ozenoxacin had high activity against Gram-positive bacteria irrespective of their resistance/susceptibility to methicillin or nonsusceptibility/susceptibility to levofloxacin.

A comparison of MIC₉₀ values in SSTI-derived isolates (Table 4) demonstrated that ozenoxacin (0.5 mg/l) was more active against CNS isolates than 19 of 22 comparator agents tested including vancomycin and linezolid (2 mg/l); moxifloxacin (4 mg/l); amoxicillin-clavulanate and teicoplanin (8 mg/l); levofloxacin (>8 mg/l); fusidic acid and trimethoprim-sulfamethoxazole (16 mg/l); meropenem (>16 mg/l); ampicillin, neomycin and tetracycline (32 mg/l); ceftriaxone and clarithromycin (>32 mg/l); penicillin and piperacillin/tazobactam (64 mg/l); and mupirocin, ceftazidime and cefuroxime (>64 mg/l). Retapamulin was the only comparator tested to have a MIC₉₀ value (0.12 mg/l) lower than that of ozenoxacin, while tigecycline and daptomycin each had a MIC₉₀ value (0.5 mg/l) equivalent to that of ozenoxacin.

Against *S. aureus* specifically (Table 4), ozenoxacin was equally as active as mupirocin, retapamulin, tigecycline and trimethoprim-sulfamethoxazole (MIC₉₀ of 0.25 mg/l), and was more active than 18 of 22 comparator

Table 1. Categorization of isolates (n = 10,054) from skin and soft tissue infections, respiratory tract infections, urinary tract infections and other or unknown sources (≥ 10 in ≥ 1 category).

Group	Pathogen	SSTI	RTI	UTI	Unknown	Other	Total
Gram-positive							
Coagulase-negative staphylococci (CNS)	All CNS	618	106	1	146	18	889
	<i>Staphylococcus capitis</i>	30	8		12	3	53
	<i>Staphylococcus epidermidis</i>	365	47		86	9	507
	<i>Staphylococcus haemolyticus</i>	76	18		11	1	106
	<i>Staphylococcus hominis</i>	48	20		22	4	94
	<i>Staphylococcus lugdunensis</i>	53	4		6		63
	<i>Staphylococcus pettenkoferi</i>	10	1		3		14
	<i>Staphylococcus warneri</i>	7	4		4	1	16
<i>Staphylococcus aureus</i>	<i>Staphylococcus aureus</i>	1518	666	1	196	17	2398
β -haemolytic streptococci	All β -haemolytic streptococci	953	118	5	127	7	1210
	<i>Streptococcus agalactiae</i>	271	11	5	37	3	327
	<i>Streptococcus dysgalactiae</i>	172	28		21	1	222
	<i>Streptococcus pyogenes</i>	507	78		69	3	657
Viridans streptococci	All Viridans streptococci	353	64	1	108	7	533
	<i>Streptococcus anginosus</i>	91	11		14	1	117
	<i>Streptococcus constellatus</i>	60	6		4		70
	<i>Streptococcus gallolyticus</i>	38	2	1	19		60
	<i>Streptococcus intermedius</i>	15	4		3		22
	<i>Streptococcus mitis</i>	29	13		21	2	65
	<i>Streptococcus oralis</i>	39	8		12	1	60
	<i>Streptococcus parasanguinis</i>	18	4		4		26
	<i>Streptococcus salivarius</i>	23	7		10	1	41
	<i>Streptococcus sanguinis</i>	10	1		7	1	19
<i>Streptococcus pneumoniae</i>	<i>Streptococcus pneumoniae</i>	63	843		18	3	927
Enterococci	All Enterococci	84	8	41	26	7	166
	<i>Enterococcus faecalis</i>	81	7	39	26	6	159
Gram-negative							
Enterobacteriaceae	All Enterobacteriaceae	895	1329	70	208	688	3190
	<i>Citrobacter freundii</i>	50	33	8	4	38	133
	<i>Citrobacter koseri</i>	40	34	10	1	34	119
	<i>Klebsiella aerogenes</i>	54	45	4	4	51	158
	<i>Enterobacter cloacae</i>	73	74	2	5	65	219
	<i>Escherichia coli</i>	287	508	17	5	234	1051
	<i>Klebsiella oxytoca</i>	51	100	6		40	197
	<i>Klebsiella pneumoniae</i>	94	350	11	2	87	544
	<i>Morganella morganii</i>	144	44	3	2	40	233
	<i>Salmonella</i> spp.	15	5	3	106	34	163
	<i>Serratia marcescens</i>	61	117	4	6	44	232
	<i>Shigella flexneri</i>		1	2	32	5	40
	<i>Shigella sonnei</i>	3	2		34	2	41
Other Gram-negative bacteria	<i>Haemophilus</i> spp.	11	525		3	9	548
	<i>Haemophilus influenzae</i>	3	458		2	7	470
	<i>Haemophilus parainfluenzae</i>	8	62		1	2	73
	<i>Moraxella catarrhalis</i>	4	169	6		1	180
	<i>Neisseria gonorrhoeae</i>	2		7	4		13

RTI: Respiratory tract infection; SSTI: Skin and soft tissue infection; UTI: Urinary tract infection.

Table 2. Concentrations of antibacterial agent tested for each bacteria.

Antibacterial	Antibacterial range tested (mg/l)					
	Staphylococci and Enterococci	<i>Streptococcus</i> spp. (other than <i>S. pneumoniae</i>)	<i>Streptococcus pneumoniae</i> and <i>Moraxella catarrhalis</i>	Enterobacteriaceae	<i>Haemophilus</i> spp.	<i>Neisseria gonorrhoeae</i>
Ozenoxacin	0.001–2	0.001–2	0.001–2	0.001–2	0.001–2	0.001–2
Mupirocin	0.03–64	0.03–64				
Fusidic acid	0.03–64	0.03–64				
Levofloxacin	0.004–8	0.03–64	0.03–64	0.004–8	0.008–16	0.004–4
Moxifloxacin	0.004–8	0.015–32	0.015–32	0.004–8	0.008–16	0.004–4
Ciprofloxacin				0.002–4		0.004–4
Ampicillin	0.015–32	0.008–16	0.015–32	0.015–32	0.008–16	
Amoxicillin-clavulanate	0.015–32	0.008–16	0.008–16	0.015–32	0.015–32	
Cefuroxime	0.03–64	0.008–16	0.008–16	0.03–64	0.015–16	0.008–1
Ceftriaxone	0.03–32	0.004–8	0.004–8	0.015–32	0.004–8	0.004–0.5
Ceftazidime	0.03–64	0.015–16	0.015–16	0.03–64	0.008–16	
Clarithromycin	0.03–32	0.015–32	0.015–32		0.015–32	
Daptomycin	0.015–32	0.015–32	0.015–16			
Linezolid	0.015–32	0.015–32	0.015–32			
Meropenem	0.008–16	0.008–16	0.008–16	0.004–8	0.008–16	
Neomycin	0.03–64	0.03–64		0.03–64		
Penicillin G	0.03–64	0.008–16	0.008–16		0.008–16	0.015–8
Piperacillin				0.06–128	0.06–128	
Piperacillin-tazobactam	0.03–64	0.015–32	0.03–64	0.06–128	0.03–64	
Retapamulin	0.008–16	0.008–16				
Teicoplanin	0.015–32	0.015–32	0.015–32			
Tetracycline	0.03–64	0.03–64	0.03–64		0.03–64	0.015–8
Tigecycline	0.004–4	0.004–4	0.002–4	0.004–8	0.002–4	
Trimethoprim-sulfamethoxazole	0.015–32	0.015–32	0.015–32		0.015–32	
Vancomycin	0.03–64	0.03–32	0.015–32			0.001–2

antibacterial agents tested that had MIC₉₀ values of 0.5 mg/l (fusidic acid and daptomycin); 1 mg/l (teicoplanin and vancomycin); 2 mg/l (linezolid); 4 mg/l (moxifloxacin); >8 mg/l (levofloxacin); 16 mg/l (amoxicillin/clavulanic acid and meropenem); 32 mg/l (tetracycline); >32 mg/l (ampicillin, ceftriaxone and clarithromycin); 64 mg/l (penicillin and piperacillin-tazobactam); and >64 mg/l (ceftazidime, cefuroxime and neomycin).

Ozenoxacin was consistently among the most active antibacterial agents (as measured by MIC₉₀) against individual CNS spp. derived from SSTIs (Table 4). Ozenoxacin was the most active agent against *Staphylococcus capitis* (0.06 mg/l) and *S. lugdunensis* (0.015 mg/l). Ozenoxacin was the fourth most active agent against *S. epidermidis* (1 mg/l) after retapamulin, daptomycin and tigecycline in order. Ozenoxacin and mupirocin were equal-second most active agents against *S. haemolyticus* (0.25 mg/l) after retapamulin. Ozenoxacin was the third most active agent against *S. hominis* (1 mg/l) after retapamulin and daptomycin.

Resistance rates to fusidic acid identified in several staphylococcal species (*S. aureus* spp. [n = 2398]: 6.5%; methicillin-resistant *S. aureus* [MRSA; n = 1053]: 8.5%; methicillin-susceptible *S. aureus* [MSSA; n = 1345]: 5.1%; and CNS spp. [n = 889]: 24.6%) were higher when antimicrobial activity was tested in isolates derived from SSTIs (*S. aureus* spp. [n = 1518]: 7.8%; CNS spp. [n = 618]: 24.1%; *S. capitis* [n = 30]: 16.7%; *S. epidermidis* [n = 365]: 26.8%; *S. haemolyticus* [n = 76]: 26.3%; and *S. hominis* [n = 48]: 33.3%). Resistance rates to mupirocin in these same species were (*S. aureus* spp.: 4.8%; MRSA: 9.0%; MSSA: 1.6%; and CNS spp.: 27.8%); and in isolates derived from SSTIs were (*S. aureus* spp.: 4.7%; CNS spp.: 27.7%; *S. capitis*: 6.7%; *S. epidermidis*: 40.5%; *S. haemolyticus*: 5.3%; and *S. hominis*: 22.9%).

Table 3. Summary minimum inhibitory concentration data of ozenoxacin stratified by methicillin resistance/susceptibility and/or levofloxacin susceptibility/nonsusceptibility for Gram-positive bacteria (staphylococci, streptococci and enterococci).

Pathogen	Levofloxacin susceptibility	n	Ozenoxacin MIC (mg/l)		
			MIC ₅₀	MIC ₉₀	Range
<i>Staphylococcus aureus</i>	All	2398	0.004	0.25	≤0.001–2
	Levofloxacin nonsusceptible	877	0.12	0.25	0.002–2
	Levofloxacin susceptible	1521	0.004	0.004	≤0.001–2
– Methicillin-resistant <i>S. aureus</i> (MRSA)	All	1053	0.12	0.25	≤0.001–2
	Levofloxacin nonsusceptible	769	0.12	0.25	≤0.001–2
	Levofloxacin susceptible	284	0.004	0.008	0.002–2
– Methicillin-susceptible <i>S. aureus</i> (MSSA)	All	1345	0.004	0.008	≤0.001–2
	Levofloxacin nonsusceptible	108	0.12	1	0.004–2
	Levofloxacin susceptible	1237	0.004	0.004	≤0.001–0.5
Coagulase-negative staphylococci (CNS)	All	889	0.015	0.25	≤0.001–2
	Levofloxacin nonsusceptible	395	0.12	1	0.03–2
	Levofloxacin susceptible	494	0.008	0.015	≤0.001–0.12
– Methicillin-resistant CNS	All	500	0.12	1	≤0.001–2
	Levofloxacin nonsusceptible	346	0.12	1	0.03–2
	Levofloxacin susceptible	154	0.008	0.015	≤0.001–0.03
– Methicillin-susceptible CNS	All	389	0.008	0.12	0.002–2
	Levofloxacin nonsusceptible	49	0.12	2	0.03–2
	Levofloxacin susceptible	340	0.008	0.015	0.002–0.12
<i>Staphylococcus capitis</i>	All	53	0.008	0.12	0.002–0.12
	Levofloxacin nonsusceptible	13	0.06	0.12	0.03–0.12
	Levofloxacin susceptible	40	0.008	0.008	0.002–0.015
– Methicillin-resistant <i>S. capitis</i>	All	23	0.008	0.12	0.004–0.12
	Levofloxacin nonsusceptible	11	0.06	0.12	0.03–0.12
	Levofloxacin susceptible	12	0.008	0.008	0.004–0.008
– Methicillin-susceptible <i>S. capitis</i>	All	30	0.008	0.008	0.002–0.12
	Levofloxacin nonsusceptible	2	0.06	0.12	0.03–0.12
	Levofloxacin susceptible	28	0.008	0.008	0.002–0.15
<i>Staphylococcus epidermidis</i>	All	507	0.06	1	≤0.001–2
	Levofloxacin nonsusceptible	265	0.12	2	0.03–2
	Levofloxacin susceptible	242	0.008	0.015	≤0.001–0.03
– Methicillin-resistant <i>S. epidermidis</i>	All	337	0.12	1	≤0.001–2
	Levofloxacin nonsusceptible	237	0.12	2	0.03–2
	Levofloxacin susceptible	100	0.008	0.015	≤0.001–0.015
– Methicillin-susceptible <i>S. epidermidis</i>	All	170	0.008	0.12	0.002–2
	Levofloxacin nonsusceptible	28	0.12	2	0.06–2
	Levofloxacin susceptible	142	0.008	0.015	0.002–0.03
<i>Staphylococcus haemolyticus</i>	All	106	0.12	0.25	0.002–1
	Levofloxacin nonsusceptible	67	0.12	0.25	0.03–1
	Levofloxacin susceptible	39	0.004	0.008	0.002–0.008
– Methicillin-resistant <i>S. haemolyticus</i>	All	73	0.12	0.25	0.004–1
	Levofloxacin nonsusceptible	62	0.12	0.25	0.06–1
	Levofloxacin susceptible	11	0.004	0.008	0.004–0.008
– Methicillin-susceptible <i>S. haemolyticus</i>	All	33	0.008	0.12	0.002–0.25
	Levofloxacin nonsusceptible	5	0.12	0.25	0.03–0.25
	Levofloxacin susceptible	28	0.004	0.008	0.002–0.008

MIC: Minimum inhibitory concentration.

Table 3. Summary minimum inhibitory concentration data of ozenoxacin stratified by methicillin resistance/susceptibility and/or levofloxacin susceptibility/nonsusceptibility for Gram-positive bacteria (staphylococci, streptococci and enterococci) (cont.).

Pathogen	Levofloxacin susceptibility	n	Ozenoxacin MIC (mg/l)		
			MIC ₅₀	MIC ₉₀	Range
<i>Staphylococcus hominis</i>	All	94	0.008	0.25	0.002–2
	Levofloxacin nonsusceptible	33	0.12	2	0.03–2
	Levofloxacin susceptible	61	0.008	0.008	0.002–0.12
– Methicillin-resistant <i>S. hominis</i>	All	51	0.06	1	0.004–2
	Levofloxacin nonsusceptible	29	0.12	2	0.03–2
	Levofloxacin susceptible	22	0.008	0.015	0.004–0.015
– Methicillin-susceptible <i>S. hominis</i>	All	43	0.008	0.06	0.002–1
	Levofloxacin nonsusceptible	4	0.12	1	0.06–1
	Levofloxacin susceptible	39	0.008	0.008	0.002–0.12
<i>Staphylococcus lugdunensis</i>	All	63	0.015	0.015	0.004–0.25
	Levofloxacin nonsusceptible	3	0.25	0.25	0.12–0.25
	Levofloxacin susceptible	60	0.015	0.015	0.004–0.03
– Methicillin-resistant <i>S. lugdunensis</i>	All	2	0.008	0.12	0.008–0.12
	Levofloxacin nonsusceptible	1	0.12	0.12	0.12–0.12
	Levofloxacin susceptible	1	0.008	0.008	0.008–0.008
– Methicillin-susceptible <i>S. lugdunensis</i>	All	61	0.015	0.015	0.004–0.25
	Levofloxacin nonsusceptible	2	0.25	0.25	0.25–0.25
	Levofloxacin susceptible	59	0.015	0.03	0.004–0.03
<i>Staphylococcus pettenkoferi</i>	All	14	0.5	0.5	0.004–1
	Levofloxacin nonsusceptible	10	0.5	1	0.12–1
	Levofloxacin susceptible	4	0.008	0.03	0.004–0.03
– Methicillin-resistant <i>S. pettenkoferi</i>	All	4	0.5	1	0.03–1
	Levofloxacin nonsusceptible	3	0.5	1	0.5–1
	Levofloxacin susceptible	1	0.03	0.03	0.03–0.03
– Methicillin-susceptible <i>S. pettenkoferi</i>	All	10	0.12	0.5	0.004–1
	Levofloxacin nonsusceptible	7	0.5	1	0.12–1
	Levofloxacin susceptible	3	0.008	0.008	0.004–0.008
– <i>Staphylococcus warneri</i>	All	16	0.008	0.015	0.004–0.015
	Levofloxacin nonsusceptible	3	0.008	0.015	0.008–0.015
	Levofloxacin susceptible	13	0.008	0.015	0.004–0.015
β-haemolytic streptococci	All	1210	0.03	0.03	0.004–2
– <i>Streptococcus agalactiae</i>	All	327	0.03	0.06	0.008–1
	Levofloxacin nonsusceptible	8	1	1	0.25–1
	Levofloxacin susceptible	319	0.03	0.06	0.008–0.12
– <i>Streptococcus dysgalactiae</i>	All	222	0.03	0.03	0.008–0.25
	Levofloxacin nonsusceptible	5	0.25	0.25	0.06–0.25
	Levofloxacin susceptible	217	0.015	0.03	0.008–0.25
– <i>Streptococcus pyogenes</i>	All	657	0.015	0.03	0.004–2
	Levofloxacin nonsusceptible	2	0.06	2	0.06–2
	Levofloxacin susceptible	655	0.015	0.03	0.004–0.12
Viridans streptococci	All	533	0.03	0.06	≤0.001–2
– <i>Streptococcus anginosus</i>	All	117	0.015	0.03	≤0.001–0.06
– <i>Streptococcus constellatus</i>	All	70	0.015	0.03	≤0.001–0.06
– <i>Streptococcus cristatus</i>	All	3	0.015	0.03	0.015–0.03
– <i>Streptococcus equinus</i>	All	6	0.015	0.06	0.015–0.06

MIC: Minimum inhibitory concentration.

Table 3. Summary minimum inhibitory concentration data of ozenoxacin stratified by methicillin resistance/susceptibility and/or levofloxacin susceptibility/nonsusceptibility for Gram-positive bacteria (staphylococci, streptococci and enterococci) (cont.).

Pathogen	Levofloxacin susceptibility	n	Ozenoxacin MIC (mg/l)		
			MIC ₅₀	MIC ₉₀	Range
– <i>Streptococcus gallolyticus</i>	All	60	0.03	0.06	0.008–2
	Levofloxacin nonsusceptible	4	0.12	2	0.06–2
	Levofloxacin susceptible	56	0.03	0.06	0.008–0.12
– <i>Streptococcus intermedius</i>	All	22	0.015	0.03	0.004–0.06
– <i>Streptococcus mitis</i>	All	65	0.03	0.06	0.015–0.5
	Levofloxacin nonsusceptible	2	0.25	0.5	0.25–0.5
	Levofloxacin susceptible	63	0.03	0.06	0.015–0.06
– <i>Streptococcus oralis</i>	All	60	0.03	0.06	0.015–0.25
	Levofloxacin nonsusceptible	2	0.25	0.25	0.25–0.25
	Levofloxacin susceptible	58	0.03	0.06	0.015–0.06
– <i>Streptococcus parasanguinis</i>	All	26	0.03	0.25	0.015–2
	Levofloxacin nonsusceptible	4	0.25	2	0.06–2
	Levofloxacin susceptible	22	0.03	0.03	0.015–0.06
– <i>Streptococcus peroris</i>	All	13	0.03	0.06	0.015–1
	Levofloxacin nonsusceptible	1	1	1	1–1
	Levofloxacin susceptible	12	0.03	0.06	0.015–0.06
– <i>Streptococcus salivarius</i>	All	41	0.03	0.06	0.015–0.06
– <i>Streptococcus sanguinis</i>	All	19	0.03	0.06	0.015–0.06
<i>Streptococcus pneumoniae</i>	All	927	0.03	0.03	≤0.001–2
	Levofloxacin nonsusceptible	11	0.25	2	0.06–2
	Levofloxacin susceptible	916	0.03	0.03	≤0.001–0.12
	Penicillin nonsusceptible	96	0.03	0.03	0.008–2
	Penicillin susceptible	831	0.03	0.03	≤0.001–0.5
Enterococci	All	166	0.06	1	≤0.001–2
– <i>Enterococcus faecalis</i>	All	159	0.06	1	≤0.001–2
	Levofloxacin nonsusceptible	48	1	1	0.06–2
	Levofloxacin susceptible	111	0.03	0.06	≤0.001–0.25

MIC: Minimum inhibitory concentration.

Streptococci & enterococci

Ozenoxacin was highly active against levofloxacin nonsusceptible/susceptible streptococci and *Enterococcus* spp. (Table 3) with a MIC₉₀ of 0.03 mg/l against combined β-haemolytic streptococci; 0.06 against combined viridans streptococci; 0.03 mg/l against *S. pneumoniae*; and 1 mg/l against enterococci including *E. faecalis*.

In SSTI-derived isolates (Table 4), ozenoxacin had the lowest or equal-lowest MIC₉₀ compared with 22 other antibacterial agents tested against the following bacteria: combined β-haemolytic streptococci, *S. agalactiae*, combined viridans streptococci, *S. anginosus*, *S. constellatus*, *S. oralis* and *S. pneumoniae*. The activity of ozenoxacin against remaining streptococci and enterococci was generally within one dilution of the most active compound. Against combined β-haemolytic streptococci, ozenoxacin had the lowest MIC₉₀ (0.03 mg/l) of all 23 antibacterial agents tested. Meropenem, penicillin, amoxicillin-clavulanic acid, ceftriaxone, cefuroxime and retapamulin each had a MIC₉₀ of 0.06 mg/l, while ampicillin, teicoplanin and tigecycline each had a MIC₉₀ of 0.012 mg/l. MIC₉₀ values for all other agents were higher than that of ozenoxacin: 0.25 mg/l for moxifloxacin, daptomycin, piperacillin-tazobactam and trimethoprim-sulfamethoxazole; 0.5 mg/l for vancomycin; 1 mg/l for mupirocin, levofloxacin, ceftazidime and linezolid; 4 mg/l for clarithromycin; 16 mg/l for fusidic acid; and 64 mg/l for tetracycline and neomycin.

Against *E. faecalis* (Table 4), tigecycline (MIC₉₀ of 0.12 mg/l) was the most active agent, followed by amoxicillin-clavulanic acid and tetracycline (both 0.05 mg/dl), then ozenoxacin and ampicillin (both 1 mg/dl).

Table 4. Comparative minimum inhibitory concentration data of ozenoxacin and other antibacterial agents for Gram-positive isolates from skin and soft tissue infections.																										
Pathogen	MIC (mg/l)	Antimicrobial agent(s)																								
		OZN	MUP	FUS	LVX	MXF	AMC	AMP	CAZ	CRO	CXM	CLR	DAP	LZD	MEM	NEO	PEN	TZP	RET	TEC	TET	TGC	SXT	VAN		
All coagulase-negative staphylococci (CNS) (n = 618)	MIC ₅₀	0.015	0.25	0.12	0.25	0.12	0.5	2	16	8	2	16	0.5	1	1	0.25	4	1	0.06	2	0.5	0.12	0.5	2		
	MIC ₉₀	0.5	>64	16	>8	4	8	32	>64	>32	>64	>32	0.5	2	>16	32	64	64	0.12	8	32	0.5	16	2		
Staphylococcus capitis (n = 30)	MIC ₅₀	0.008	0.12	0.12	0.25	0.06	0.12	0.25	4	2	0.5	0.25	0.5	1	0.12	0.06	1	0.5	0.06	0.5	0.25	0.12	0.06	1		
	MIC ₉₀	0.06	0.5	8	4	1	4	>32	64	>32	>64	>32	1	2	8	16	>64	64	0.12	0.5	2	0.25	0.25	2		
Staphylococcus epidermidis (n = 365)	MIC ₅₀	0.06	0.25	0.25	2	0.5	1	4	16	8	4	32	0.5	1	2	0.25	4	1	0.06	4	1	0.12	0.5	2		
	MIC ₉₀	1	>64	16	>8	>8	8	16	64	>32	>64	>32	0.5	2	16	32	32	32	0.12	8	32	0.5	16	2		
Staphylococcus haemolyticus (n = 76)	MIC ₅₀	0.12	0.12	0.12	8	1	4	32	>64	>32	64	32	0.25	1	8	2	64	16	0.06	4	1	0.25	1	1		
	MIC ₉₀	0.25	0.25	16	>8	4	>32	>32	>64	>32	>64	>32	0.5	1	>16	64	>64	>64	0.12	8	32	0.5	>32	2		
Staphylococcus hominis (n = 48)	MIC ₅₀	0.008	0.25	0.12	0.12	0.06	0.5	1	32	8	1	32	0.25	1	1	0.06	0.5	2	0.06	0.5	0.25	0.12	4	1		
	MIC ₉₀	1	>64	16	>8	8	2	16	>64	32	8	>32	0.25	2	4	4	16	8	0.12	4	64	0.5	8	1		
Staphylococcus lugdunensis (n = 53)	MIC ₅₀	0.015	0.12	0.12	0.12	0.06	0.25	0.25	16	4	1	0.06	0.25	1	0.25	0.25	0.12	0.5	0.03	0.5	0.12	0.06	0.25	1		
	MIC ₉₀	0.015	0.12	0.25	0.25	0.12	1	4	16	4	2	>32	0.25	1	0.5	0.25	4	1	0.06	0.5	0.25	0.06	0.5	1		
Staphylococcus aureus (n = 1518)	MIC ₅₀	0.004	0.12	0.12	0.25	0.06	1	8	16	4	2	0.25	0.5	2	0.12	0.5	16	2	0.12	0.5	0.25	0.12	0.06	1		
	MIC ₉₀	0.25	0.25	0.5	>8	4	16	>32	>64	>32	>64	>32	0.5	2	16	>64	64	64	0.25	1	32	0.25	0.25	1		
All β-haemolytic streptococci (n = 953)	MIC ₅₀	0.03	0.12	8	0.5	0.12	0.015	0.015	0.25	0.03	0.015	0.03	0.06	1	≤0.008	32	0.015	0.06	0.03	0.06	0.25	0.06	0.06	0.5		
	MIC ₉₀	0.03	1	16	1	0.25	0.06	0.12	1	0.06	0.06	4	0.25	1	0.06	64	0.06	0.25	0.06	0.12	64	0.12	0.25	0.5		
Streptococcus agalactiae (n = 271)	MIC ₅₀	0.03	1	16	1	0.12	0.06	0.12	0.5	0.06	0.06	0.03	0.25	1	0.06	64	0.06	0.25	0.03	0.12	32	0.06	0.12	0.5		
	MIC ₉₀	0.06	1	32	1	0.25	0.06	0.12	1	0.06	0.06	>32	0.25	1	0.06	>64	0.06	0.25	0.06	0.12	64	0.12	0.12	0.5		
Streptococcus dysgalactiae (n = 172)	MIC ₅₀	0.03	0.12	4	0.5	0.12	0.015	0.03	0.25	0.03	0.015	0.03	0.06	1	0.015	32	≤0.008	0.06	0.03	0.12	0.25	0.06	0.12	0.25		
	MIC ₉₀	0.03	0.25	8	1	0.25	0.03	0.03	0.5	0.03	0.015	1	0.12	1	0.015	32	0.015	0.12	0.06	0.12	32	0.25	0.12	0.5		
Streptococcus pyogenes (n = 507)	MIC ₅₀	0.03	0.06	8	0.5	0.12	0.015	0.015	0.12	0.015	0.015	0.03	0.06	1	≤0.008	32	≤0.008	0.06	0.03	0.06	0.25	0.06	0.06	0.5		
	MIC ₉₀	0.03	0.25	8	1	0.25	0.015	0.03	0.25	0.03	0.015	0.5	0.06	1	≤0.008	64	0.015	0.06	0.06	0.12	32	0.06	0.25	0.5		
AMC: Amoxicillin/Clavulanate; AMP: Ampicillin; CAZ: Ceftazidime; CLR: Clarithromycin; CRO: Ceftriaxone; CXM: Cefuroxime; DAP: Daptomycin; FUS: Fusidic acid; LVX: Levofloxacin; LZD: Linezolid; MEM: Meropenem; MIC: Minimum inhibitory concentration; MUP: Mupirocin; MXF: Moxifloxacin; ND: Not done; NEO: Neomycin; OZN: Ozenoxacin; PEN: Penicillin; RET: Retapamulin; SXT: Sulfamethoxazole/trimethoprim; TEC: Teicoplanin; TET: Tetracycline; TGC: Tigecycline; TZP: Piperacillin/tazobactam; VAN: Vancomycin.																										

Table 4. Comparative minimum inhibitory concentration data of ozenoxacin and other antibacterial agents for Gram-positive isolates from skin and soft tissue infections (cont.).

Pathogen	MIC (mg/l)	Antimicrobial agent(s)														
		OZN	MUP	FUS	LVX	MXF	AMC	AMP	CAZ	GRO	CXM	CLR	DAP	LZD	MEM	NEO
All Viridans streptococci (n = 353)	MIC ₅₀	0.03	0.5	16	1	0.12	0.06	0.06	2	0.12	0.12	0.03	0.25	1	0.03	32
	MIC ₉₀	0.06	1	64	2	0.25	0.5	1	8	0.25	1	>32	1	2	0.12	64
<i>Streptococcus anginosus</i> (n = 91)	MIC ₅₀	0.015	0.5	8	0.5	0.12	0.06	0.06	2	0.12	0.12	0.03	0.25	1	0.06	32
	MIC ₉₀	0.03	0.5	16	1	0.25	0.12	0.12	4	0.25	0.25	0.5	0.5	2	0.06	64
<i>Streptococcus constellatus</i> (n = 60)	MIC ₅₀	0.015	0.5	16	0.5	0.12	0.03	0.06	2	0.12	0.12	≤0.015	0.25	1	0.06	32
	MIC ₉₀	0.03	1	32	0.5	0.12	0.12	0.25	8	0.25	0.25	0.03	0.5	1	0.12	64
<i>Streptococcus gallolyticus</i> (n = 38)	MIC ₅₀	0.03	1	32	1	0.12	0.06	0.06	0.5	0.06	0.06	0.06	0.06	1	0.015	8
	MIC ₉₀	0.12	1	64	2	0.25	0.12	0.12	1	0.12	0.25	>32	0.5	2	0.03	64
<i>Streptococcus oralis</i> (n = 39)	MIC ₅₀	0.03	1	32	1	0.12	0.06	0.06	2	0.12	0.25	0.25	1	1	0.03	64
	MIC ₉₀	0.06	8	32	2	0.25	4	4	>16	4	>16	>32	1	2	1	>64
<i>Streptococcus pneumoniae</i> (n = 63)	MIC ₅₀	0.03	ND	ND	1	0.12	0.015	0.03	0.25	0.03	0.03	0.03	0.12	1	0.015	ND
	MIC ₉₀	0.03	ND	ND	1	0.25	2	4	16	1	8	>32	0.25	1	0.5	ND
All Enterococci (n = 84)	MIC ₅₀	0.06	32	4	1	0.25	0.5	1	>64	>32	>64	16	1	2	4	>64
	MIC ₉₀	1	64	4	>8	>8	0.5	1	>64	>32	>64	>32	4	2	8	>64
<i>Enterococcus faecalis</i> (n = 81)	MIC ₅₀	0.06	32	4	1	0.25	0.5	1	>64	>32	>64	16	1	2	4	>64
	MIC ₉₀	1	64	4	>8	>8	0.5	1	>64	>32	>64	>32	4	2	8	>64

AMC: Amoxicillin/Clavulanate; AMP: Ampicillin; CAZ: Ceftazidime; CLR: Clarithromycin; CRO: Ceftriaxone; CXM: Cefuroxime; DAP: Daptomycin; FUS: Fusidic acid; LVX: Levofloxacin; LZD: Linezolid; MEM: Meropenem; MIC: Minimum inhibitory concentration; MUP: Mupirocin; MXF: Moxifloxacin; ND: Not done; NEO: Neomycin; OZN: Ozenoxacin; PEN: Penicillin; RET: Retapamulin; SXT: Sulfamethoxazole/trimethoprim; TEC: Telcoplanin; TET: Tetracycline; TGC: Tigecycline; TZP: Piperacillin/tazobactam; VAN: Vancomycin.

Table 5. Summary minimum inhibitory concentration data of ozenoxacin for Gram-negative bacteria.

Pathogen	n	Ozenoxacin MIC (mg/l)		
		MIC ₅₀	MIC ₉₀	Range
All Enterobacteriaceae	3190	0.25	>2	0.004–>2
– <i>Citrobacter braakii</i>	11	1	>2	0.06–>2
– <i>Citrobacter freundii</i>	133	0.25	>2	0.03–>2
– <i>Citrobacter koseri</i>	119	0.06	0.12	0.015–>2
– <i>Klebsiella aerogenes</i>	158	0.25	>2	0.03–>2
– <i>Enterobacter asburiae</i>	21	0.12	0.5	0.03–>2
– <i>Enterobacter cloacae</i>	219	0.12	>2	0.015–>2
– <i>Enterobacter kobei</i>	11	0.25	>2	0.03–>2
– <i>Escherichia coli</i>	1051	0.06	>2	0.004–>2
– <i>Klebsiella oxytoca</i>	197	0.25	1	0.03–>2
– <i>Klebsiella pneumoniae</i>	544	0.25	>2	0.008–>2
– <i>Morganella morganii</i>	233	0.25	>2	0.03–>2
– <i>Salmonella</i> spp.	163	0.12	0.5	0.015–>2
– <i>Serratia marcescens</i>	232	1	>2	0.004–>2
– <i>Shigella flexneri</i>	40	0.03	0.5	0.008–>2
– <i>Shigella sonnei</i>	41	0.03	0.25	0.008–>2
Other Gram-negative bacteria				
– <i>Haemophilus</i> spp.	548	0.004	0.03	≤0.001–2
– <i>Haemophilus influenza</i>	470	0.004	0.015	≤0.001–1
– <i>Haemophilus parainfluenza</i>	73	0.03	0.25	≤0.001–2
– <i>Moraxella catarrhalis</i>	180	0.004	0.008	≤0.001–0.03
– <i>Neisseria gonorrhoeae</i>	13	0.12	1	≤0.001–2

MIC: Minimum inhibitory concentration.

Gram-negative bacteria

Enterobacteriaceae

Ozenoxacin had a MIC₉₀ of more than 2 mg/l for combined species of the Enterobacteriaceae family, with values ranging from 0.12 mg/l for *Citrobacter koseri*, 0.25 mg/l for *Shigella sonnei*, 0.5 mg/l for *Enterobacter asburiae* and *S. flexneri*, 1 mg/l for *Klebsiella oxytoca*, and more than 2 mg/l for all remaining species (Table 5).

MIC values against Gram-negative bacteria derived from SSTIs were compared for ozenoxacin and 13 other antibacterial agents. Based on MIC₉₀, ozenoxacin was the most active quinolone against combined Enterobacteriaceae, *E. cloacae*, *E. coli*, *K. pneumoniae* and *Morganella morganii*. In contrast, ozenoxacin was the least active quinolone against *C. freundii*, *C. koseri*, *E. aerogenes*, *K. oxytoca* and *Serratia marcescens*. However, the quinolones were generally of similar activity with MIC₉₀ values within one or two dilutions of each other.

For combined species of Enterobacteriaceae, the most active compounds (as measured by MIC₉₀) were meropenem (0.06 mg/l), tigecycline (2 mg/l) and ozenoxacin (>2 mg/l), followed by neomycin (4 mg/l), ciprofloxacin (>4 mg/l), levofloxacin and moxifloxacin (each >8 mg/l). All other antibacterial agents had MIC₉₀ values of 32 to >128 mg/l (Table 6).

Other Gram-negative bacteria

For other Gram-negative bacteria (Table 5), ozenoxacin was highly active against *Haemophilus* spp. (MIC₉₀ of 0.03 mg/l), *H. influenzae* (0.015 mg/l) and *Moraxella catarrhalis* (0.008 mg/l), and was somewhat less active against *H. parainfluenzae* (0.25 mg/l) and *Neisseria gonorrhoeae* (1 mg/l), although it was tested on only 13 *N. gonorrhoeae* isolates.

Ozenoxacin and levofloxacin (MIC₉₀ of 0.015 mg/l) were the second most active antibacterial agents against *H. influenzae* after ceftriaxone (0.008 mg/l), followed by piperacillin/tazobactam (≤0.03 mg/l), moxifloxacin (0.03 mg/l), meropenem (0.06 mg/l) and ceftazidime (0.12 mg/l); all other antibacterial agents had MIC₉₀ values of 0.5–16 mg/l.

Table 6. Comparative minimum inhibitory concentration data (mg/l) of ozenoxacin and other antibacterial agents for Gram-negative isolates from skin and soft tissue infections.

Pathogen	MIC (mg /l)	Antimicrobial agent													
		OZN	LVX	MXF	CIP	AMC	AMP	CAZ	CRO	CXM	MEM	NEO	PIP	TZP	TGC
All Enterobacteriaceae (n = 895)	MIC ₅₀	0.25	0.06	0.12	0.03	16	>32	0.25	0.06	8	0.03	1	8	2	0.5
	MIC ₉₀	>2	>8	>8	>4	>32	>32	32	>32	>64	0.06	4	>128	32	2
<i>Citrobacter freundii</i> (n = 50)	MIC ₅₀	0.25	0.12	0.25	0.015	32	32	0.5	0.25	4	0.03	1	4	2	1
	MIC ₉₀	>2	1	1	0.5	>32	>32	>64	>32	>64	0.06	2	>128	64	2
<i>Citrobacter koseri</i> (n = 40)	MIC ₅₀	0.06	0.03	0.03	0.008	2	32	0.12	0.06	4	0.015	0.5	8	2	0.5
	MIC ₉₀	0.12	0.06	0.06	0.015	8	>32	0.5	0.25	8	0.03	1	64	8	1
<i>Klebsiella aerogenes</i> (n = 54)	MIC ₅₀	0.25	0.06	0.12	0.015	>32	>32	0.25	0.12	8	0.03	0.5	4	4	0.5
	MIC ₉₀	0.5	0.12	0.12	0.03	>32	>32	64	32	>64	0.06	1	128	64	1
<i>Enterobacter cloacae</i> (n = 73)	MIC ₅₀	0.12	0.06	0.06	0.015	>32	>32	0.5	0.25	16	0.03	0.5	4	4	1
	MIC ₉₀	>2	4	4	4	>32	>32	>64	>32	>64	0.06	1	>128	128	2
<i>Escherichia coli</i> (n = 287)	MIC ₅₀	0.06	0.06	0.06	0.015	8	>32	0.25	0.03	4	0.015	2	>128	2	0.25
	MIC ₉₀	>2	>8	>8	>4	32	>32	32	>32	>64	0.03	4	>128	32	0.5
<i>Klebsiella oxytoca</i> (n = 51)	MIC ₅₀	0.25	0.06	0.06	0.015	1	>32	0.12	0.06	4	0.03	0.5	16	2	0.5
	MIC ₉₀	0.5	0.12	0.25	0.06	4	>32	0.25	0.12	8	0.03	4	64	8	1
<i>Klebsiella pneumoniae</i> (n = 94)	MIC ₅₀	0.25	0.06	0.12	0.03	4	>32	0.5	0.06	4	0.03	1	16	4	1
	MIC ₉₀	>2	>8	>8	>4	>32	>32	>64	>32	>64	0.06	8	>128	>128	2
<i>Morganella morganii</i> (n = 144)	MIC ₅₀	0.5	0.06	0.25	0.015	>32	>32	0.12	0.03	32	0.06	2	4	0.25	2
	MIC ₉₀	>2	8	>8	>4	>32	>32	16	4	>64	0.12	32	>128	1	8
<i>Serratia marcescens</i> (n = 61)	MIC ₅₀	1	0.12	0.25	0.06	>32	>32	0.25	0.25	>64	0.03	1	4	2	2
	MIC ₉₀	>2	2	2	1	>32	>32	4	>32	>64	0.06	2	128	32	4

AMC: Amoxicillin/Clavulanate; AMP: Ampicillin; CAZ: Ceftazidime; CIP: Ciprofloxacin; CRO: Ceftriaxone; CXM: Cefuroxime; LVX: Levofloxacin; MEM: Meropenem; MIC: Minimum inhibitory concentration; MXF: Moxifloxacin; NEO: Neomycin; OZN: Ozenoxacin; PIP: Piperacillin; TGC: Tigecycline; TZP: Piperacillin/tazobactam.

AMC: Amoxicillin/Clavulanate; AMP: Ampicillin; CAZ: Ceftazidime; CIP: Ciprofloxacin; CRO: Ceftriaxone; CXM: Cefuroxime; LVX: Levofloxacin; MEM: Meropenem; MIC: Minimum inhibitory concentration; MXF: Moxifloxacin; NEO: Neomycin; OZN: Ozenoxacin; PIP: Piperacillin; TZP: Tigecycline; TGC: Tigecycline; TGP: Piperacillin/tazobactam.

All quinolones were less active against *H. parainfluenzae* than *H. influenzae*. Ceftriaxone (MIC₉₀ of 0.008 mg/l) was the most active antibacterial agent against this species, followed by ceftazidime and meropenem (0.06 mg/l), levofloxacin (0.12 mg/l), then ozenoxacin, moxifloxacin and piperacillin/tazobactam (0.25 mg/l); all other antibacterial agents had MIC₉₀ values of 1–16 mg/l.

Ozenoxacin and meropenem were the most active agents against *M. catarrhalis* (MIC₉₀ of ≤ 0.008 mg/l), followed by piperacillin/tazobactam (≤ 0.03 mg/l), levofloxacin and moxifloxacin (0.06 mg/l), and clarithromycin (0.12 mg/l); all other agents had MIC₉₀ values of 0.25–16 mg/l.

Discussion

A previously published study that compared the antimicrobial activity of ozenoxacin versus 17 antibacterial agents in more than 2000 Gram-positive clinical isolates from SSTIs showed that ozenoxacin is a potent antimicrobial agent against both staphylococci and streptococci, irrespective of levofloxacin susceptibility status [14]. The current comparative study examined the antibacterial activity of ozenoxacin in Gram-positive and Gram-negative clinical isolates derived mainly from SSTIs, RTIs and UTIs, which were stratified according to their methicillin and levofloxacin susceptibility status. The antibacterial activity of ozenoxacin was compared with that of 22 other antibacterial agents against approximately 4500 Gram-positive SSTI isolates, and with that of 13 other antibacterial agents against approximately 900 Gram-negative SSTIs isolates and Gram-negative isolates from other sources (e.g., RTIs, UTIs, etc).

Against Gram-positive isolates from SSTIs, ozenoxacin was highly active against staphylococci and streptococci, confirming the results of previously published comparative studies [14]. Ozenoxacin had a lower MIC₉₀ than mupirocin and fusidic acid against the CNS isolates *S. capitis*, *S. epidermidis*, *S. hominis* and *S. lugdunensis*, and against combined β -haemolytic streptococci, combined viridans streptococci, all other subspecies of streptococci, and enterococci. Ozenoxacin was equally active as mupirocin (as measured by MIC₉₀) against *S. haemolyticus* and *S. aureus*. These results confirm and extend the previously reported results showing higher activity of ozenoxacin compared with mupirocin and fusidic acid against staphylococci and streptococci [14].

Clinical breakpoints of antibiotics are calculated based on MIC distributions, and pharmacokinetic and pharmacodynamic data (area under the curve of plasma concentrations). Because topical antibiotics are minimally absorbed, clinical breakpoints cannot be determined. Instead, combined MIC distributions from multiple sources and time periods are used to define epidemiological cutoffs that provide an indication of MICs for organisms with acquired or mutational resistance mechanisms. The inferred breakpoint for mupirocin is 1/256 mg/l and applies to topical nasal administration three-times daily. It is based on microbiological data (epidemiological cutoffs) and clinical experience [20]. In the case of fusidic acid, breakpoints for *Staphylococcus* spp. are $S \leq 1$ mg/l and $R > 1$ mg/l for an oral or IV dosage of 500 mg two- to three-times daily. The breakpoints are based on pharmacokinetic data, microbiological data and clinical experience [21]. In the current study, BSAC disk diffusion breakpoints that are harmonized with the European Committee on Antimicrobial Testing were used for susceptibility testing of mupirocin and fusidic acid [18]. Disk diffusion tests with ozenoxacin have yet to be conducted but are planned. According to the BSAC breakpoints in this study, the resistance rate of *S. aureus* to mupirocin and fusidic acid was higher in MRSA isolates than in MSSA isolates (9.0 and 1.6% for mupirocin and 8.5 and 5.1% for fusidic acid, respectively).

Fusidic acid, mupirocin or retapamulin are the main topical treatments recommended in Europe for treatment of impetigo [22], although resistance of staphylococcal strains to these agents is becoming a concern. Resistance to fusidic acid [23–27] and mupirocin [28–30] has been reported in Europe and may be increasing. Investigators in Greece reported a sevenfold increase from 2013 to 2016 in the rate of mupirocin-resistant *S. aureus* strains among community-associated staphylococcal infections (mainly impetigo cases), concurrent with a 1.9-fold increase in resistance rates to fusidic acid [31], highlighting the need for alternatives. Ozenoxacin's dual inhibitory activity against DNA gyrase and topoisomerase IV, in addition to other characteristics such as a mutant prevention concentration below that in skin, appear to protect it from the development of resistance [10].

Elsewhere, a Japanese comparative study of ozenoxacin with other antibacterial agents against cutaneous bacterial isolates from pediatric patients reported MIC₉₀ values for ozenoxacin of 0.12, ≤ 0.06 and ≤ 0.06 mg/l against MRSA, MSSA and *S. pyogenes* isolates, respectively [32]. Respective MIC₉₀ values for gentamicin against MRSA, MSSA and *S. pyogenes* isolates in this same Japanese study were more than 128, 64 and 4 mg/l for SSTIs from adults and 128, 16 and 4 mg/l for SSTIs from children. Gentamicin is used topically to treat SSTIs in some countries

but was not included in the present study. The Japanese results highlight that ozenoxacin is markedly more active than gentamicin against the most common Gram-positive bacteria found in SSTIs.

Another Japanese study showed that MICs of ozenoxacin against three levofloxacin-susceptible *Propionibacterium acnes* strains (MIC of levofloxacin; ≤ 4 $\mu\text{g/ml}$) and three levofloxacin-resistant *P. acnes* strains (MIC of levofloxacin; ≥ 8 $\mu\text{g/ml}$) ranged from 0.03 to 0.06 $\mu\text{g/ml}$ and from 0.25 to 0.5 $\mu\text{g/ml}$, respectively [33]. These results suggest that ozenoxacin has a potent bactericidal activity against both levofloxacin-susceptible and levofloxacin-resistant *P. acnes*, a microorganism not included in the present study. A 2% lotion formulation of ozenoxacin has been approved since 2015 in Japan for treatment of inflamed acne.

In this study, the quinolones (ozenoxacin, ciprofloxacin, levofloxacin and moxifloxacin) exhibited comparable activity against Enterobacteriaceae, whereas ozenoxacin was the most active quinolone against *E. cloacae*, *E. coli*, *K. pneumoniae* and *M. morganii*. Ozenoxacin had lower activity than other quinolones against *C. freundii*, *C. koseri*, *K. aerogenes*, *K. oxytoca* and *S. marcescens*, although the differences were relatively small.

As SSTIs are caused mainly by Gram-positive cocci (especially *S. aureus* and *S. pyogenes*), the numbers of Gram-negative isolates derived exclusively from SSTIs were insufficient to compare ozenoxacin with other antibacterial agents. Moreover, other commonly used topical antibiotics such as mupirocin [34] and fusidic acid [35] have no or limited activity against Gram-negative isolates. The vast majority of *Haemophilus* spp. and *M. catarrhalis* isolates were derived from RTIs. Nevertheless, irrespective of the source, ozenoxacin was highly active against all *Haemophilus* spp. (0.03 mg/l), *H. influenzae* (0.015 mg/l) and *M. catarrhalis* (MIC₉₀ of 0.008 mg/l), and was somewhat less active against *H. parainfluenzae* (0.25 mg/l).

Conclusion

In conclusion, ozenoxacin was shown to be a potent antibacterial agent against Gram-positive (staphylococci and streptococci) isolates and showed activity against some Gram-negative isolates. The high activity of ozenoxacin in staphylococcal and streptococcal spp. including methicillin and quinolone-resistant strains most commonly associated with childhood impetigo suggests that ozenoxacin may be a valuable alternative to other topical antibiotics in the eradication of these same bacterial species derived from SSTIs.

Summary points

- Ozenoxacin, a novel nonfluorinated quinolone with bactericidal activity, is approved in the USA, Canada and 12 EU countries as a 1% cream formulation for treatment of impetigo and in Japan as a 2% lotion formulation for treatment of superficial skin infections and acne.
- During development of ozenoxacin, surveillance studies compared its *in vitro* antibacterial activity with that of other topical and systemic antibacterial agents.
- In 2010, a total of 10,054 Gram-positive and Gram-negative isolates were collected from 128 centers worldwide; isolates were derived mainly from skin and soft tissue infections (SSTIs; 44.8%) and respiratory tract infections (38.1%).
- Minimum inhibitory concentrations were determined for 23 and 13 antimicrobial agents, respectively, using standard broth microdilution methods.
- Ozenoxacin exhibited high *in vitro* activity against susceptible, and methicillin- or levofloxacin-resistant, Gram-positive bacteria (*Staphylococcus aureus*, coagulase-negative staphylococci, β -haemolytic streptococci, viridans streptococci, enterococci and *Streptococcus pneumoniae* isolates).
- In the case of Gram-positive SSTI isolates, ozenoxacin was generally more active than mupirocin or fusidic acid and other quinolones.
- Ozenoxacin showed one or two dilutions less activity against Enterobacteriaceae isolates, except for *Escherichia coli*, than other quinolones tested.
- In the case of Gram-negative SSTI isolates, no comparisons of ozenoxacin were made with mupirocin and fusidic acid as these antibiotics are not active against these bacteria.
- Ozenoxacin is a potent antimicrobial agent mainly against susceptible and resistant strains of Gram-positive isolates (staphylococci and streptococci), and shows activity against some Gram-negative isolates.

Financial & competing interests disclosure

The studies were supported by Ferrer Internacional, Barcelona, Spain. I Morrissey is an employee of IHMA Europe who has received payment from numerous pharmaceutical companies to perform *in vitro* research on antimicrobial activity. R Canton, J Vila, M

García-Castillo and Y López have received research grants from Ferrer Internacional. D Gargallo-Viola is a former employee of Ferrer Internacional. I Zsolt is a current employee of Ferrer Internacional. The authors have no other relevant affiliations or financial involvements with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was provided by Content Ed Net (Madrid, Spain) with funding from Ferrer International SA (Barcelona, Spain).

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

Open access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>

References

Papers of special note have been highlighted as: ● of interest; ●● of considerable interest

- Bolognia J, Jorizzo JL, Schaffer JV. Bacterial diseases. In: *Dermatology. 3rd Edition*. Bolognia J, Jorizzo JL, Schaffer JV (Eds.). Saunders, Philadelphia, PA, USA, 1187–1189 (2012).
- Sladden MJ, Johnston GA. Common skin infections in children. *BMJ* 329, 95–99 (2004).
- Abeck D. Staphylococcal and streptococcal diseases. In: *Braun-Falco's Dermatology*. Burgdorf W, Plewig G, Wolff HH, Landthaler M (Eds). Springer-Verlag Berlin Heidelberg, 114–139 (2009).
- Garbe C, Wolf G. Topical therapy. In: *Braun-Falco's Dermatology*. Burgdorf W, Plewig G, Wolff HH, Landthaler M (Eds). Springer-Verlag Berlin Heidelberg, 1549–1572 (2009).
- Edge R, Argáez C (Eds). Topical antibiotics for impetigo: a review of the clinical effectiveness and guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. *CADTH Rapid Response Reports* (2017). <https://www.cadth.ca/sites/default/files/pdf/htis/2017/RC0851%20Topical%20Antibiotics%20for%20Impetigo%20Final.pdf>
- Yamakawa T, Mitsuyama J, Hayashi K. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. *J. Antimicrob. Chemother.* 49(3), 455–465 (2002).
- Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX™ (ozenoxacin cream 1%). (2019). <https://www.newswire.ca/news-releases/cipher-pharmaceuticals-receives-health-canada-approval-of-ozanex-ozenoxacin-cream-1-621597383.html>
- MHRA. Summary of product characteristics: ozadub 10 mg/g cream. Ozenoxacin. (2019). <http://www.mhra.gov.uk/spc-pil/?subsName=OZENOXACIN&pageID=SecondLevel>
- Health Products Regulatory Authority. Summary of product characteristics: dubine 10 mg/g cream. Ozenoxacin. (2019). <https://www.hpra.ie/homepage/medicines-information/find-a-medicine/results?query=OZENOXACIN&field=ACTIVESUBSTANCES>
- Vila J, Hebert AA, Torrelo A *et al.* Ozenoxacin: a review of preclinical and clinical efficacy. *Expert Rev. Anti. Infect. Ther.* 17(3), 159–168 (2019).
- **Comprehensive review of the microbiology, pharmacodynamic and pharmacokinetic properties of ozenoxacin, and its clinical and microbiological efficacy in impetigo.**
- Gropper S, Albareda N, Chelius K *et al.* Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. *Future Microbiol.* 9, 1013–1023 (2014).
- **Phase III clinical trial demonstrating the efficacy and safety of ozenoxacin 1% cream for treatment of impetigo.**
- Rosen T, Albareda N, Rosenberg N *et al.* Efficacy and safety of ozenoxacin cream for treatment of adult and pediatric patients with impetigo: a randomized clinical trial. *JAMA Dermatol.* 154, 806–813 (2018).
- **Phase III clinical trial demonstrating the efficacy and safety of ozenoxacin 1% cream for treatment of impetigo.**
- López Y, Tato M, Espinal P *et al.* In vitro activity of ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria. *Antimicrob. Agents Chemother.* 57, 6389–6392 (2013).
- Cantón R, Morrissey I, Vila J *et al.* Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates. *Future Microbiol.* 13, 3–19 (2018).
- **Comparison of the in vitro activity of ozenoxacin versus other antibacterial agents against Gram-positive clinical isolates from skin and soft tissue infections.**
- Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline. CLSI Document M45-A. CLSI, Wayne, Pennsylvania 19087–1898, USA (2006).
- Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard – Eighth Edition. CLSI Document M7-A8. CLSI, Wayne, Pennsylvania 19087–1898, USA (2009).

17. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI Document M100-S20. CLSI, Wayne, Pennsylvania 19087–1898, USA (2010).
18. British Society for Antimicrobial Chemotherapy. BSAC Methods for Antimicrobial Susceptibility Testing. Version 9.1 March 2010 (2010). http://bsac.org.uk/wp-content/uploads/2012/02/Version_9.1_March_2010_final-v2.pdf
19. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement. CLSI Document M100-S21, Wayne, PA, USA (2011).
20. European Committee on Antimicrobial Susceptibility Testing. Mupirocin: rationale for the clinical breakpoints, version 1.0, 2010. <http://www.eucast.org>
21. European Committee on Antimicrobial Susceptibility Testing. Fusidic acid: rationale for the clinical breakpoints, version 1.0, 2010. <http://www.eucast.org>
22. van Bijnen EM, Paget WJ, den Heijer CD *et al.* Primary care treatment guidelines for skin infections in Europe: congruence with antimicrobial resistance found in commensal *Staphylococcus aureus* in the community. *BMC Fam. Pract.* 15, 175 (2014).
23. Howden BP, Grayson ML. Dumb and dumber – the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in *Staphylococcus aureus*. *Clin. Infect. Dis.* 42, 394–400 (2006).
24. O'Neill AJ, Larsen AR, Skov R *et al.* Characterization of the epidemic European fusidic acid-resistant impetigo clone of *Staphylococcus aureus*. *J. Clin. Microbiol.* 45, 1505–1510 (2007).
25. Denton M, O'Connell B, Bernard P *et al.* The EPISA study: antimicrobial susceptibility of *Staphylococcus aureus* causing primary or secondary skin and soft tissue infections in the community in France, the UK and Ireland. *J. Antimicrob. Chemother.* 61, 586–588 (2008).
26. Alsterholm M, Flytström I, Bergbrant IM *et al.* Fusidic acid-resistant *Staphylococcus aureus* in impetigo contagiosa and secondarily infected atopic dermatitis. *Acta Derm. Venereol.* 90, 52–57 (2010).
27. Castanheira M, Watters AA, Mendes RE *et al.* Occurrence and molecular characterization of fusidic acid resistance mechanisms among *Staphylococcus* spp. from European countries (2008). *J. Antimicrob. Chemother.* 65, 1353–1358 (2010).
28. Rossney A, O'Connell S. Emerging high-level mupirocin resistance among MRSA isolates in Ireland. *Euro. Surveill.* 13, 8084 (2008).
29. Sareyyupoglu B, Ozyurt M, Haznedaroglu T *et al.* Detection of methicillin and mupirocin resistance in staphylococcal hospital isolates with a touchdown multiplex polymerase chain reaction. *Folia Microbiol. (Praha)* 53, 363–367 (2008).
30. Desroches M, Potier J, Laurent F *et al.* Prevalence of mupirocin resistance among invasive coagulase-negative staphylococci and methicillin-resistant *Staphylococcus aureus* (MRSA) in France: emergence of a mupirocin-resistant MRSA clone harbouring mupA. *J. Antimicrob. Chemother.* 68, 1714–1717 (2013).
31. Doudoulakakis A, Spiliopoulou I, Spyridis N *et al.* Emergence of a *Staphylococcus aureus* clone resistant to mupirocin and fusidic acid carrying exotoxin genes and causing mainly skin infections. *J. Clin. Microbiol.* 55, 2529–2537 (2017).
- **Greek investigators describe emergence of a *Staphylococcus aureus* clone resistant to mupirocin and fusidic acid.**
32. Kanayama S, Ikeda F, Okamoto K *et al.* *In vitro* antimicrobial activity of ozenoxacin against methicillin-susceptible *Staphylococcus aureus*, methicillin-resistant *S. aureus* and *Streptococcus pyogenes* isolated from clinical cutaneous specimens in Japan. *J. Infect. Chemother.* 22, 720–723 (2016).
- ***In vitro* antibacterial activity of ozenoxacin against cutaneous isolates in Japan.**
33. Kanayama S, Okamoto K, Ikeda F *et al.* Bactericidal activity and post-antibiotic effect of ozenoxacin against *Propionibacterium acnes*. *J. Infect. Chemother.* 23(6), 374–380 (2017).
- ***In vitro* antibacterial activity of ozenoxacin against *Propionibacterium acnes*.**
34. Ward A, Campoli-Richards DM. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. *Drugs* 32(5), 425–444 (1986).
35. Verbist L. The antimicrobial activity of fusidic acid. *J. Antimicrob. Chemother.* 25(Suppl. B), 1–5 (1990).